Literature DB >> 15157916

Advances in cell therapy for renal failure.

H David Humes1, Mark S Szczypka.   

Abstract

Cell therapy is one of the most exciting fields in translational medicine. It stands at the intersection of a variety of rapidly developing scientific disciplines: stem cell biology, immunology, tissue engineering, molecular biology, biomaterials, transplantation biology, regenerative medicine and clinical research. Cell-based therapy may develop into a new therapeutic platform to treat a vast array of clinical disorders. Blood transfusions and bone marrow transplantation are prime examples of the successful application of cell-based therapeutics; but recent advances in cellular and molecular biology have expanded the potential applications of this approach. Although recombinant genetic engineering to produce a variety of therapeutics, such as human erythropoietin and insulin has proven successful, these treatments are unable to completely correct or reverse disease states, because most common disease processes are not due to the deficiency of a single protein but develop due to alterations in the complex interactions of a variety of cell components. In these complex situations, cell-based therapy may be a more successful strategy by providing a dynamic, interactive and individualized therapeutic approach that responds to the pathophysiological condition of the patient. In this regard, cells may provide innovative methods for drug delivery of biologics, immunotherapy, and tissue regenerative or replacement engineering [Nature 392 (1998) 518-524, Nat Biotechnol 20 (2002) 339-343]. The translation of this discipline to medicinal practice has tremendous potential, but in many applications technological issues need to be overcome. Since many cell-based indications are already being evaluated in the clinic, the field appears to be on the threshold of a number of successes. This review will focus on our group's use of human stem/progenitor cells in the treatment of acute and chronic renal failure as extensions to current successful renal substitution processes of hemodialysis and hemofiltration. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Year:  2004        PMID: 15157916     DOI: 10.1016/j.trim.2003.12.015

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  6 in total

Review 1.  Biomaterials approach to expand and direct differentiation of stem cells.

Authors:  Chou Chai; Kam W Leong
Journal:  Mol Ther       Date:  2007-01-30       Impact factor: 11.454

2.  Lipocalin 2 enhances mesenchymal stem cell-based cell therapy in acute kidney injury rat model.

Authors:  Mehryar Habibi Roudkenar; Raheleh Halabian; Hossein Abdul Tehrani; Fatemeh Amiri; Ali Jahanian-Najafabadi; Amaneh Mohammadi Roushandeh; Zahra Abbasi-Malati; Yoshikazu Kuwahara
Journal:  Cytotechnology       Date:  2017-06-02       Impact factor: 2.058

3.  Near-infrared lipophilic fluorophores for tracing tissue growth.

Authors:  Soon Hee Kim; Gwangli Park; Hoon Hyun; Jeong Heon Lee; Yoshitomo Ashitate; Jungmun Choi; Gloria H Hong; Eric A Owens; Maged Henary; Hak Soo Choi
Journal:  Biomed Mater       Date:  2013-01-25       Impact factor: 3.715

4.  Bone Marrow Mononuclear Cells Restore Normal Mitochondrial Ca2+ Handling and Ca2+-Induced Depolarization of the Internal Mitochondrial Membrane by Inhibiting the Permeability Transition Pore After Ischemia/Reperfusion.

Authors:  Clara Rodrigues-Ferreira; Jarlene Alécia Lopes; Priscila Fonseca Carneiro; Cristiane Dos Santos Lessa; Antonio Galina; Adalberto Vieyra
Journal:  Cell Transplant       Date:  2022 Jan-Dec       Impact factor: 4.064

5.  Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure.

Authors:  Steve J Hodges; Anthony Atala
Journal:  Curr Urol Rep       Date:  2006-01       Impact factor: 2.862

6.  In Situ Tissue Regeneration of Renal Tissue Induced by Collagen Hydrogel Injection.

Authors:  Sang Jin Lee; Hung-Jen Wang; Tae-Hyoung Kim; Jin San Choi; Gauri Kulkarni; John D Jackson; Anthony Atala; James J Yoo
Journal:  Stem Cells Transl Med       Date:  2018-02       Impact factor: 6.940

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.